Literature DB >> 21117058

Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease.

Carlton Haywood1, Mary Catherine Beach, Shawn Bediako, C Patrick Carroll, Lakshmi Lattimer, Dasheema Jarrett, Sophie Lanzkron.   

Abstract

The attitudes of patients with sickle cell disease (SCD) toward the use of hydroxyurea (HU) therapy may contribute to the underutilization of HU in the United States, yet our understanding of these attitudes is limited. We examined the attitudes and beliefs of 94 adult SCD patients, comparing those who never used HU (n 5 37), formerly used HU (n 5 23), and were currently using HU (n 5 34). Seventy percent of current HU users reported some level of improvement from the drug ("average" or "very much") and 80% reported little or no trouble from side effects. Fifty-seven percent of former users reported taking HU for less than 6 months, with "doctor"s recommendation," or "not liking the way it made me feel" given as the most commonly reported reasons for stopping HU. Fifty percent of the never users reported receiving no information about HU from any source, and 85% of the never users thought that they would receive no improvement if they were to take HU. A deeper understanding of patient perspectives toward HU utilization is required as part of multipronged efforts to combat its underutilization in the treatment of SCD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21117058      PMCID: PMC3233349          DOI: 10.1002/ajh.21883

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  19 in total

1.  NIH consensus development statement on hydroxyurea treatment for sickle cell disease.

Authors:  Otis W Brawley; Llewellyn J Cornelius; Linda R Edwards; Vanessa Northington Gamble; Bettye L Green; Charles E Inturrisi; Andra H James; Danielle Laraque; Magda H Mendez; Carolyn J Montoya; Brad H Pollock; Lawrence Robinson; Aaron P Scholnik; Melissa Schori
Journal:  NIH Consens State Sci Statements       Date:  2008 Feb 27-29

2.  The cost of health care for patients with sickle cell disease.

Authors:  Samir K Ballas
Journal:  Am J Hematol       Date:  2009-06       Impact factor: 10.047

3.  Therapy preference and decision-making among patients with severe sickle cell anemia and their families.

Authors:  Jane Hankins; Pamela Hinds; Sara Day; Yvonne Carroll; Chin-Shang Li; Patricia Garvie; Winfred Wang
Journal:  Pediatr Blood Cancer       Date:  2007-06-15       Impact factor: 3.167

Review 4.  Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease.

Authors:  Sophie Lanzkron; John J Strouse; Renee Wilson; Mary Catherine Beach; Carlton Haywood; HaeSong Park; Catherine Witkop; Eric B Bass; Jodi B Segal
Journal:  Ann Intern Med       Date:  2008-05-05       Impact factor: 25.391

Review 5.  Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.

Authors:  John J Strouse; Sophie Lanzkron; Mary Catherine Beach; Carlton Haywood; Haeseong Park; Catherine Witkop; Renee F Wilson; Eric B Bass; Jodi B Segal
Journal:  Pediatrics       Date:  2008-12       Impact factor: 7.124

6.  The cost of health care for children and adults with sickle cell disease.

Authors:  Teresa L Kauf; Thomas D Coates; Liu Huazhi; Nikita Mody-Patel; Abraham G Hartzema
Journal:  Am J Hematol       Date:  2009-06       Impact factor: 10.047

7.  Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea.

Authors:  Matthew Olnes; Amy Chi; Carissa Haney; Rose May; Caterina Minniti; James Taylor; Gregory J Kato
Journal:  Am J Hematol       Date:  2009-08       Impact factor: 10.047

8.  Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network.

Authors:  Sophie Lanzkron; Carlton Haywood; Kathryn L Hassell; Cynthia Rand
Journal:  J Natl Med Assoc       Date:  2008-08       Impact factor: 1.798

9.  Development and evaluation of a patient empowerment video to promote hydroxyurea adoption in sickle cell disease.

Authors:  Jennifer M LaVista; Debbie M Treise; Levette N Dunbar; Jane Ritho; Abraham G Hartzema; Richard Lottenberg
Journal:  J Natl Med Assoc       Date:  2009-03       Impact factor: 1.798

10.  Hydroxyurea and sickle cell anemia: effect on quality of life.

Authors:  Samir K Ballas; Franca B Barton; Myron A Waclawiw; Paul Swerdlow; James R Eckman; Charles H Pegelow; Mabel Koshy; Bruce A Barton; Duane R Bonds
Journal:  Health Qual Life Outcomes       Date:  2006-08-31       Impact factor: 3.186

View more
  23 in total

1.  Do difficulties in swallowing medication impede the use of hydroxyurea in children?

Authors:  ElShadey Bekele; Courtney D Thornburg; Amanda M Brandow; Mukta Sharma; Arlene M Smaldone; Zhezhen Jin; Nancy S Green
Journal:  Pediatr Blood Cancer       Date:  2014-04-17       Impact factor: 3.167

2.  The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice.

Authors:  Shuaiying Cui; Kim-Chew Lim; Lihong Shi; Mary Lee; Natee Jearawiriyapaisarn; Greggory Myers; Andrew Campbell; David Harro; Shigeki Iwase; Raymond C Trievel; Angela Rivers; Joseph DeSimone; Donald Lavelle; Yogen Saunthararajah; James Douglas Engel
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

3.  Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy.

Authors:  Robert S Nickel; Ifeyinwa Osunkwo; Aneesah Garrett; Jennifer Robertson; David R Archer; Daniel E L Promislow; John T Horan; Jeanne E Hendrickson; Leslie S Kean
Journal:  Br J Haematol       Date:  2015-03-05       Impact factor: 6.998

4.  Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study.

Authors:  Jason R Hodges; Shannon M Phillips; Sarah Norell; Chinonyelum Nwosu; Hamda Khan; Lingzi Luo; Sherif M Badawy; Allison King; Paula Tanabe; Marsha Treadwell; Lucia Rojas Smith; Cecelia Calhoun; Jane S Hankins; Jerlym Porter
Journal:  Blood Adv       Date:  2020-09-22

5.  The Role of Patient-Physician Communication on the Use of Hydroxyurea in Adult Patients with Sickle Cell Disease.

Authors:  Sarah M Jabour; Sara Beachy; Shayna Coburn; Sophie Lanzkron; Michelle N Eakin
Journal:  J Racial Ethn Health Disparities       Date:  2019-08-13

6.  Digital behavioural interventions for people with sickle cell disease.

Authors:  Sherif M Badawy; Robert M Cronin; Robert I Liem; Tonya M Palermo
Journal:  Cochrane Database Syst Rev       Date:  2021-04-27

Review 7.  Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine.

Authors:  Min Dong; Patrick T McGann
Journal:  Clin Pharmacol Ther       Date:  2020-10-08       Impact factor: 6.875

8.  Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease.

Authors:  Suzette O Oyeku; M Catherine Driscoll; Hillel W Cohen; Rebecca Trachtman; Farzana Pashankar; Craig Mullen; Patricia J Giardina; Nerissa Velazco; Andrew D Racine; Nancy S Green
Journal:  Pediatr Blood Cancer       Date:  2012-11-05       Impact factor: 3.167

9.  Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease.

Authors:  Mariam Kayle; Jhaqueline Valle; Susan Paulukonis; Jane L Holl; Paula Tanabe; Dustin D French; Ravi Garg; Robert I Liem; Sherif M Badawy; Marsha J Treadwell
Journal:  Pediatr Blood Cancer       Date:  2020-03-08       Impact factor: 3.167

10.  Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use.

Authors:  Nancy Crego; Christian Douglas; Emily Bonnabeau; Marian Earls; Kern Eason; Elizabeth Merwin; Gary Rains; Paula Tanabe; Nirmish Shah
Journal:  J Am Board Fam Med       Date:  2020 Jan-Feb       Impact factor: 2.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.